Hans Bigalke

3.0k total citations
63 papers, 2.1k citations indexed

About

Hans Bigalke is a scholar working on Neurology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Hans Bigalke has authored 63 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Neurology, 27 papers in Cellular and Molecular Neuroscience and 14 papers in Molecular Biology. Recurrent topics in Hans Bigalke's work include Botulinum Toxin and Related Neurological Disorders (53 papers), Neurological disorders and treatments (32 papers) and Hereditary Neurological Disorders (18 papers). Hans Bigalke is often cited by papers focused on Botulinum Toxin and Related Neurological Disorders (53 papers), Neurological disorders and treatments (32 papers) and Hereditary Neurological Disorders (18 papers). Hans Bigalke collaborates with scholars based in Germany, United States and United Kingdom. Hans Bigalke's co-authors include E. Habermann, Dirk Dressler, Florian Dreyer, Andreas Rummel, Raymond L. Rosales, Gregory K. Bergey, Gudrun Ahnert‐Hilger, B Bizzini, Wilfried Dimpfel and P. G. Nelson and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Hans Bigalke

62 papers receiving 2.0k citations

Peers

Countries citing papers authored by Hans Bigalke

Since Specialization

Citations

This map shows the geographic impact of Hans Bigalke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Bigalke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Bigalke more than expected).

Fields of papers citing papers by Hans Bigalke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Bigalke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Bigalke. The network helps show where Hans Bigalke may publish in the future.

Co-authorship network of co-authors of Hans Bigalke

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Bigalke. A scholar is included among the top collaborators of Hans Bigalke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Bigalke. Hans Bigalke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Botulinum toxin antibody titres: measurement, interpretation, and practical recommendations 2022 ·Journal of Neurology ·Dirk Dressler, John C. Rothwell, Kailash P. Bhatia, Bruno Kopp, Hans Bigalke, Fereshte Adib Saberi	4
2	Long‐term adherence and response to botulinum toxin in different indications 2020 ·Annals of Clinical and Translational Neurology ·John‐Ih Lee, (unknown), Sara Samadzadeh, (unknown), Marek Moll, Marius Ringelstein, (unknown), Hans Bigalke, Orhan Aktaş, (unknown), (unknown), Sebastian Jander, Michael Gliem, Alfons Schnitzler, Hans‐Peter Hartung, Harald Hefter, Philipp Albrecht	18
3	Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy 2019 ·Neurology ·Philipp Albrecht, (unknown), John‐Ih Lee, Orhan Aktaş, Hans Bigalke, Hans‐Peter Hartung, Harald Hefter	3
4	Comparing lanbotulinumtoxinA (Hengli®) with onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in the mouse hemidiaphragm assay 2019 ·Journal of Neural Transmission ·(unknown), Hans Bigalke, Bruno Kopp, Lingjing Jin, Dirk Dressler	4
5	High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy 2018 ·Neurology ·Philipp Albrecht, (unknown), John‐Ih Lee, Marek Moll, Marius Ringelstein, Dietmar Rosenthal, Hans Bigalke, Orhan Aktaş, Hans‐Peter Hartung, Harald Hefter	95
6	Reconstituting botulinum toxin drugs: shaking, stirring or what? 2016 ·Journal of Neural Transmission ·Dirk Dressler, Hans Bigalke	12
7	Results of a BoNT/A Antibody Study in Children and Adolescents after Onabotulinumtoxin A (Botox®) Detrusor Injection 2011 ·Urologia Internationalis ·Heinrich Schulte‐Baukloh, (unknown), Hans Bigalke, K. Miller, Helmut H. Knispel	13
8	Antibody-Induced Failure of Botulinum Toxin A Therapy in Cosmetic Indications 2010 ·Dermatologic Surgery ·Dirk Dressler, (unknown), (unknown), Luitgard Wiest, Hans Bigalke	45
9	Neutralizing Antibodies and Secondary Therapy Failure After Treatment With Botulinum Toxin Type A 2009 ·Clinical Neuropharmacology ·Oliver Lange, Hans Bigalke, Reinhard Dengler, Florian Wegner, (unknown), Kai Wohlfarth	107
10	Botulinum toxin A does not alter capsaicin-induced pain perception in human skin 2007 ·Journal of the Neurological Sciences ·Wilhelm Schulte‐Mattler, Oliver Opatz, (unknown), Arne May, Hans Bigalke, (unknown)	25
11	Secondary non‐response due to antibody formation in a child after three injections of botulinum toxin B into the salivary glands 2006 ·Developmental Medicine & Child Neurology ·Steffen Berweck, A. Sebastian Schroeder, (unknown), Hans Bigalke, Florian Heinen	26
12	Pharmacology of botulinum toxin: differences between type A preparations 2006 ·European Journal of Neurology ·Raymond L. Rosales, Hans Bigalke, Dirk Dressler	136
13	Medical aspects of toxin weapons 2005 ·Toxicology ·Hans Bigalke, Andreas Rummel	79
14	The C-terminal transmembrane region of synaptobrevin binds synaptophysin from adult synaptic vesicles 2005 ·European Journal of Cell Biology ·Sowmya V. Yelamanchili, Clemens Reisinger, Anja Becher, Stefan Sikorra, Hans Bigalke, Thomas Binz, Gudrun Ahnert‐Hilger	30
15	The synaptophysin/synaptobrevin complex dissociates independently of neuroexocytosis 2004 ·Journal of Neurochemistry ·Clemens Reisinger, Sowmya V. Yelamanchili, (unknown), Diana Mitter, Anja Becher, Hans Bigalke, Gudrun Ahnert‐Hilger	40
16	Antibody-Induced Botulinum Toxin Therapy Failure: Can It Be Overcome by Increased Botulinum Toxin Doses? 2002 ·European Neurology ·Dirk Dressler, Alexander Münchau, Kailash P. Bhatia, Niall Quinn, Hans Bigalke	40
17	Tetanus antitoxin binds to intracellular tetanus toxin in permeabilized chromaffin cells without restoring Ca2+-induced exocytosis 1990 ·Toxicon ·(unknown), Gudrun Ahnert‐Hilger, Hans H. Wellhöner, Hans Bigalke	7
18	Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons 1990 ·Neuroreport ·(unknown), Hans Bigalke	63
19	Memantine reduces repetitive action potential firing in spinal cord nerve cell cultures 1990 ·European Journal of Pharmacology ·Roman Netzer, Hans Bigalke	13
20	Tetanus toxin: Inhibitory action in chromaffin cells is initiated by specified types of gangliosides and promoted in low ionic strength solution 1989 ·Neuroscience Letters ·(unknown), Hans Bigalke	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact